ImmunoMark Summit
USA — Boston 2026
Driving Innovation in Immuno-Oncology and Biomarker Discovery
Boston's Premier
IO & Biomarker Summit
ImmunoMark Summit East Coast Edition 2026 is a premier two-day international conference dedicated to the advancing science of Immuno-Oncology and Biomarker-Driven Precision Medicine. It is designed to connect cutting-edge scientific discovery with real-world clinical, translational, and commercial oncology applications.
As immunotherapies continue to reshape cancer care — from first-generation checkpoint inhibitors to next-generation cell therapies and bispecific antibodies — the role of robust, clinically validated biomarkers has never been more critical.
Conceptualized and curated by Convolign Business Consulting, this high-impact summit in Boston — a global epicentre of biotech innovation and oncology drug development — brings together pharmaceutical and biotech leaders, translational medicine experts, diagnostic developers, clinical researchers, and regulatory authorities from across the globe.
The mission of ImmunoMark Summit is to accelerate the translation of immuno-oncology science and biomarker innovation from discovery settings into measurable clinical outcomes.
Location
Boston, USA — Global biotech capital and home to leading oncology research institutions.
Dates
7–8 October 2026
Two full conference days.
Format
Two parallel streams, networking lunches, Drinks Reception on Day 1.
Contact
anandhu@convolign.com
+1-617-604-3359
CONFERENCE STREAMS
Two Parallel Tracks
Immuno-Oncology
- Next-generation immune checkpoints & first-in-class IO assets
- CAR-T, TCR-T, and NK cell therapies for solid tumors
- Tumor microenvironment biology & resistance mechanisms
- Bispecific & multispecific immune engagers
- Antibody–drug conjugates (ADCs) & novel IO modalities
- Personalized cancer vaccines & neoantigens
- Translational models supporting IND & late-stage trials
- Managing immune-related toxicities
Biomarkers & CDx
- Biomarkers-first oncology drug development strategies
- Liquid biopsy, MRD & real-time treatment monitoring
- Single-cell, spatial biology & multi-omics technologies
- AI & machine learning for scalable biomarker discovery
- CDx co-development, regulatory pathways & commercialization
- Health economics & value demonstration of biomarkers
- FDA & global regulatory updates
- Translating biomarker data into clinical endpoints
Key Highlights
Next-Generation IO Therapies
Novel immune checkpoints, bispecific antibodies, CAR-T, TCR-T, and NK cell therapies advancing beyond current standard of care.
Biomarker-First Drug Development
Strategic frameworks for integrating predictive and prognostic biomarkers from IND through to late-stage trials and regulatory submission.
AI & Multi-Omics Discovery
How AI and machine learning are transforming biomarker identification, patient stratification, and companion diagnostic development at scale.
Liquid Biopsy & Real-Time Monitoring
Advances in ctDNA, MRD detection, and non-invasive biomarker platforms enabling dynamic treatment monitoring and earlier intervention.
Regulatory Pathways & CDx Commercialization
Navigating FDA approval strategies, CDx co-development timelines, and health economics frameworks for bringing biomarker-driven solutions to market.
Overcoming Resistance in Immunotherapy
Understanding mechanisms of primary and acquired resistance and exploring strategies to improve patient response through novel targets and combination therapies.
Why Attend
Stay Ahead of the Science
Latest data, platform innovations, and pipeline insights from world-leading IO and biomarker researchers.
Build High-Value Connections
Network with 400+ senior decision-makers through structured 1:1 sessions, panels, and a Drinks Reception.
Learn from Global Experts
Leaders from AstraZeneca, Roche, Merck, J&J, Novartis, GSK, and top academic institutions.
Unbiased, Expert-Curated Content
Agenda designed by the scientific community to reflect true industry needs — not vendor priorities.
Who Should Attend
ImmunoMark Summit East Coast Edition 2026 is tailored for a senior, multidisciplinary audience across oncology, biopharma, and life sciences:
Pharma & Biotech
CEOs, CSOs, VPs of Translational Medicine, Oncology R&D Directors, BD Executives
Biomarker & Diagnostic Teams
Scientists, Lab Heads, and CDx Developers building next-generation predictive biomarker platforms
Clinical Research
Oncologists, Clinical Trial Investigators, Translational Medicine Leads integrating biomarker strategies
Academia & Regulatory
PIs, Group Leaders, FDA/EMA representatives, Biomarker Qualification Scientists, Policy Leads
Who Will Be In The Room
Audience by Sector
Seniority Breakdown
Attendee Domains
The Global IO & Biomarker Market
The immuno-oncology and biomarker landscape represents one of the fastest-growing sectors in global life sciences. The data below illustrates the scale of the opportunity — and why ImmunoMark Summit sits at its centre.
Global IO Market Value
Projected global immuno-oncology market value.
Biomarker Discovery Market CAGR
Annual growth rate of the global biomarker discovery market.
FDA-Approved Companion Diagnostics
Approved CDx tests worldwide.
Liquid Biopsy Market by 2030
Projected liquid biopsy market size.
Trials with Biomarker Stratification
Oncology trials using biomarker endpoints.
Growth in AI-Driven Platforms
AI adoption growth in biomarker workflows.
Expert Speaker Panel
TBA
PROGRAMME
Conference Agenda
A high-intensity two-day programme spanning the full spectrum of immuno-oncology and biomarker science. Both streams run simultaneously across dedicated rooms, with shared networking breaks and a Drinks Reception on Day 1.
| Time | Stream 1: Immuno-Oncology | Stream 2: Biomarkers & CDx |
|---|---|---|
| 08:00 — Registration & Morning Coffee | ||
| 08:45 | Chairperson’s Opening Remarks (Both Streams) | |
| 09:00 | Keynote: Redefining IO Drug Development in the US | Keynote: Biomarkers-First Oncology Development |
| 09:30 | Novel Immune Checkpoints & First-in-Class IO Assets | Predictive & Prognostic Biomarkers in IO Trials |
| 10:00 | Engineering Cell Therapies for Solid Tumors | Companion Diagnostics Co-Development in the US |
| 10:00 | Engineering Cell Therapies for Solid Tumors | Companion Diagnostics Co-Development in the US |
| Time | Stream 1: Immuno-Oncology | Stream 2: Biomarkers & CDx |
|---|---|---|
| 08:00 — Registration & Morning Coffee | ||
| 09:00 | Keynote: The Future of Immunotherapy in the US Market | Keynote: Biomarkers in FDA Oncology Approvals |
| 09:30 | Neoadjuvant & Adjuvant Immunotherapy | Biomarkers for Early Detection & MRD |
| 10:00 | Emerging Immune Modulation Pathways | Proteomics & Metabolomics in Oncology |
Networking Highlights
Drinks Reception
End of Day 1 from 17:30 — informal, relationship-first networking
1:1 Meetings
Structured matchmaking with sponsors, speakers, and delegates
Networking Lunches
Shared lunches both days — cross-community connection opportunity
Sponsor Exhibition
Dedicated exhibition space running across both conference days
Our Sponsors & Partners
ImmunoMark Summit East Coast Edition 2026 is supported by leading organisations in biopharma, diagnostics, genomics, and life sciences technology. Sponsorship opportunities across all tiers remain open.
Why Sponsor ImmunoMark Summit East Coast Edition 2026
Sponsoring ImmunoMark Summit East Coast Edition 2026 places your brand at the centre of the immuno-oncology and biomarker transformation happening right now in Boston and across the US market. You gain direct access to 400+ senior decision-makers.
Unlike generic life sciences conferences, ImmunoMark is a curated, senior-audience platform engineered for deep engagement, strategic dialogue, and long-term partnerships.
Speaking Access
Reserved branded speaking slot (Platinum & Gold tiers)
Exhibition Space
Dedicated stand for demos and direct delegate engagement
Attendee List
Post-event access for structured follow-up outreach
1:1 Matchmaking
Structured meetings with your most relevant prospects
Brand Visibility
Logo across website, agenda, email, social, and on-site materials
Social Media Coverage
Pre and post-event coverage across ImmunoMark channels
Glimpses of Our Other Conferences
Experience the calibre and energy of an ImmunoMark Summit. Our London 2026 edition brought together over 400 senior life sciences professionals for two days of scientific exchange and strategic networking.
TESTIMONIALS
What Sponsors Said
Don't take our word for it. Here's what the scientists, executives and innovators who attended ImmunoMark Summit London 2026 had to say.
Venue
Boston, USA — Full venue details will be shared with registered delegates and confirmed sponsors. Boston is home to the world's most concentrated cluster of biotech and oncology innovation — the ideal location for a summit at the intersection of immunotherapy and precision medicine.
Contact Our Team Today
For registration, speaking opportunities, or sponsorship enquiries, our team is ready to assist.